Webinar: Development of an Ultra-Sensitive Human Cardiac Troponin I Sandwich ELISA

Register here      Learn more about Cavidi and Exazym technology

Detecting ultra-low levels of cardiac troponin I (cTnI) is crucial for early cardiac injury diagnosis and research, yet standard assays often fall short in sensitivity for demanding applications like biomarker studies or drug safety monitoring.

Join us for a live presentation on BOLD (Binding Oligo Ladder Detection), Cavidi’s innovative signal amplification technology that provides ultra-sensitive detection of low-abundance biomarkers using standard ELISA workflows. Led by Dr. Peter Stenlund, this webinar will demonstrate how BOLD achieved a 180-fold improved sensitivity in a human cTnI sandwich ELISA—without requiring specialized equipment or major protocol changes.

Tailored for cardiovascular researchers, cardiologists, and diagnostic scientists in biomarker discovery and clinical development, this session provides actionable strategies to elevate your ELISA-based cardiac research.

Key highlights:

• Discover a 180x Sensitivity Boost See how BOLD lowered the cTnI detection limit to 0.07 pg/mL—a 180-fold improvement over standard ELISA, enabling you to spot heart injury at its very earliest molecular stages.

• Integrate Seamlessly Learn how to incorporate BOLD into your existing ELISA workflows with minimal protocol adjustments, including optimizations for capture/detector antibodies, and temperature flexibility.

• Explore Real-World Impact Review a detailed case study on cTnI assay optimization and its relevance to cardiac research, including how it helps make more informed decisions in drug development by identifying cardiotoxic effects sooner and at lower doses, improves patient care by detecting risk before damage becomes irreversible, and unlocks new scientific insights into how heart disease develops and progresses—ultimately guiding the next generation of diagnostics and therapies.

• Gain Technical Mastery Understand the step-by-step mechanics behind BOLD signal amplification—from antibody conjugation to signal generation.

• Engage Live Get your questions answered in an interactive Q&A session with our expert.

Speaker

Dr. Peter Stenlund is a protein chemist with a PhD in biochemistry from Umeå University. His career spans roles as a senior lecturer, postdoctoral scientist in the U.S., and development scientist at Biacore, as well as senior scientist positions at Octapharma and Galderma. He brings deep expertise in analytical development for protein drug characterization. As Principal Scientist at Cavidi AB, Dr. Stenlund now leads innovation in ultra-sensitive immunoassay solutions, making him the ideal guide for this technical deep dive into BOLD signal amplification.

Event info:

• Date: November 13, 2025
• Time: 16:30 CET
• Duration: 45 minutes
• Format: Live webinar
• Capacity: Limited to 100 seats

Register here      Learn more about Cavidi and Exazym technology